TRDA
Entrada Therapeutics
$6.08
+$0.23 (+3.93%)Jul 27, 2026
Key metrics
The numbers that frame TRDA today
- Market cap
- $236.03M
- P/E (TTM)
- -1.4
- EV / FCF
- -1.6
- Gross margin
- 100%
- EV / Sales
- 35.9
- ROIC
- -48.9%
- Div yield
- 0%
- Debt / equity
- 0.2
- 52wk Low
- $4.93
- 52wk High
- $16.45
Growth
Revenue and earnings trend for TRDA
RevenueNet income
See the full growth breakdown
Revenue and earnings trends, margins and the multi-year trajectory - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inCash flow & returns
Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture
Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inInsider trading
Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade
See who is buying and selling, how much, and when - updated as new filings land.
Create a free accountFree foreverNo card required
Already a member? Log inFrequently asked questions
Plain-English answers about TRDA
Is Entrada Therapeutics a good buy?
No. Entrada Therapeutics has poor quality and weak momentum. Both signals point to a weaker setup. Growth looks mixed. The support signal is useful, but not decisive. We think Entrada Therapeutics is selling at a very high price.
What is the market capitalization of TRDA?
Entrada Therapeutics's market capitalization is $236.03M.
What is the P/E ratio for TRDA stock?
Entrada Therapeutics's current P/E ratio is -1.4.
What is the 52-week high for TRDA stock?
The 52-week high for Entrada Therapeutics is $16.45. The current close of $6.08 is 63% below that high.
What is the 52-week low for TRDA stock?
The 52-week low for Entrada Therapeutics is $4.93. The current close of $6.08 is 23.3% above that low.
Does TRDA stock pay dividends?
Entrada Therapeutics does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for TRDA?
Entrada Therapeutics's Debt / Equity ratio is 0.18.